Format

Send to

Choose Destination
Clin Perinatol. 2012 Mar;39(1):149-64. doi: 10.1016/j.clp.2011.12.006.

Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.

Author information

1
Department of Pediatrics, Children's Memorial Hospital, Northwestern University, Chicago, IL 60614, USA. n-porta@northwestern.edu

Abstract

The perinatal transition from fetal to extrauterine life requires a dramatic change in the circulatory pattern as the organ of gas exchange switches from the placenta to the lungs. Pulmonary hypertension can occur during early newborn life, and present as early respiratory failure or as a complication of more chronic diseases, such as bronchopulmonary dysplasia. The most effective pharmacotherapeutic strategies for infants with persistent pulmonary hypertension of the newborn are directed at selective reduction of pulmonary vascular resistance. This article discusses currently available therapies for pulmonary hypertension, their biologic rationales, and evidence for their clinical effectiveness.

PMID:
22341543
PMCID:
PMC3562500
DOI:
10.1016/j.clp.2011.12.006
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center